Dose changes for cancer treatment in people with Duffy null
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that needs treatment, or stage II or III triple-negative breast cancer
- You are about to start or are on your first cycle of either daratumumab-RVd for myeloma or carboplatin-paclitaxel-pembrolizumab for breast cancer
- You have a genetic blood trait called Duffy null, confirmed by a blood test
- You are 18 years old or older
- You are not taking any other experimental drugs for any condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial is for people with multiple myeloma who have already completed 12 cycles of a standard treatment (daratumumab, lenalidomide, and dexamethasone) and are doing well. It tests whether taking a break from treatment is safe and effective, instead of continuing without a break.
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
This study looks at how a specific genetic trait (Duffy-null) affects white blood cell counts and chemotherapy dosing in people of Middle Eastern or African descent. The goal is to help doctors determine the right chemotherapy dose to reduce side effects while still being effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.